ConvaTec Group Plc (CNVVY) Stock Price & Analysis
ConvaTec Group Plc (CNVVY) — price $13.90 (-1.91%), as of the Nov 20, 2026 trading session; market cap $6.63B.
Educational signal · not a buy or sell recommendation · How to read this
ConvaTec Group Plc · CNVVY · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: ConvaTec develops and distributes medical devices for wound care, ostomy management, continence solutions, and hospital critical care across more than a hundred countries. The company's financial case turns on whether persistent debt can be serviced while the business matures into steady profitability.
Price as of Nov 20, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $13.90 | |
| Change on the day | -1.91% | |
| 52-week range | $10.45–$14.09 | |
| Market capitalisation | $6.63B | — |
| Price / earnings (trailing) | 51.37 | |
| Shares traded on the day | 4.0K | |
| Beta (volatility vs the S&P 500) | 0.84 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for ConvaTec Group (CNVVY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is ConvaTec Group (CNVVY), and what does it report?
Short answer · as of
ConvaTec manufactures and distributes medical devices across four main categories: advanced wound-care products for acute and chronic wounds; ostomy care systems for patients with colostomies or ileostomies; continence solutions including intermittent catheters; and critical-care supplies for intensive-care units.
Research dated 2026-09-13.
Customers include hospitals, healthcare providers, and patients who purchase through direct channels, distributors, and wholesalers.
The reported financial statements measure manufacturing throughput, sales mix, and gross-margin realization. Operating results reflect the spread between product cost and selling price, after deducting research, commercial expenses, and administrative overhead.
What do the latest results show for ConvaTec Group (CNVVY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1.23B.
Research dated 2026-09-13.
The most recent quarter showed revenue and earnings per share both declined from the prior-year period, though the decline in reported earnings was steeper than the top-line contraction. Gross profit held as a percentage of revenue, indicating the margin pressure came from higher operating expenses rather than manufacturing cost inflation.
Management cited certain product transitions and integration headwinds as temporary factors, with a clear statement that operating margin should reach acceptable levels in the full year.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.23B | $54M | $0.11 (diluted) |
| Q4 FY2025 | $1.25B | $70M | $0.14 (diluted) |
| Q2 FY2025 | $1.18B | $105M | $0.20 (diluted) |
| Q4 FY2024 | $1.18B | $111M | $0.22 (diluted) |
What are the financial strengths and risks for ConvaTec Group (CNVVY)?
Short answer
Cash and short-term investments were $0.00 at the Dec 31, 2025 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Operating cash generation has been robust, though it fluctuates seasonally with working capital movements. The balance sheet carries significant debt relative to annual revenue and market value, with cash holdings covering only a fraction of total obligations. The company has sufficient liquidity to meet near-term needs, but leverage remains elevated.
What should you watch next at ConvaTec Group (CNVVY)?
Research dated 2026-09-13.
Watch whether the second half achieves the indicated margin recovery. Watch working capital: the company expects a seasonal reversal of cash outflows in the latter months. Watch free-cash-flow conversion to confirm management's expectation of near-total conversion to equity holders. Watch currency effects—management noted meaningful headwinds that may reverse if the dollar weakens.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
How is ConvaTec Group scored?
Research dated 2026-09-13.
ConvaTec's footprint spans specialty healthcare (wound care, ostomy) rather than broad hospital supply or home health. Compared to diversified medical-device distributors, it holds a narrower product portfolio but deeper expertise in its chosen segments. Geographic presence covers developed markets primarily, with growing presence in emerging markets but less penetration than some larger competitors.
| Company | Price | Market value | Score |
|---|---|---|---|
| $14.21 Nov 20, 2026 | $7.14B | — Model unavailable | |
| $2.36 Nov 20, 2026 | $4.13B | — Model unavailable | |
| $26.89 Nov 20, 2026 | $7.32B | — Model unavailable | |
| $6.87 Nov 20, 2026 | $5.09B | — Model unavailable | |
| $13.34 Nov 20, 2026 | $8.03B | — Model unavailable | |
| $161.58 Nov 20, 2026 | $6.41B | — 5-pillar · not comparable | |
| $20.69 Nov 19, 2026 | $7.40B | — 5-pillar · not comparable | |
| $120.16 Nov 20, 2026 | $5.47B | — 5-pillar · not comparable | |
| $84.34 Nov 20, 2026 | $5.05B | — 5-pillar · not comparable | |
| $140.08 Nov 20, 2026 | $8.88B | — 5-pillar · not comparable | |
| $14.84 Nov 20, 2026 | $10.1B | — 5-pillar · not comparable | |
| $172.52 Nov 20, 2026 | $4.31B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CNVVY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CNVVY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about ConvaTec Group (CNVVY)?
- ConvaTec Group PLC (OTCMKTS:CNVVY) Stock Short Interest Climbs 19,836.3%
- JP Morgan says ConvaTec guidance looks increasingly secure ahead of trading update
- Convatec Survey Challenges Assumptions About Leakage in Ostomy Care
- Convatec Expands Cure™ Portfolio With Launch of Cure Aqua™, Bringing Greater Choice to People Who Catheterize
CNVVY Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
Why does ConvaTec maintain such high debt levels?
The debt likely reflects prior acquisition strategy or dividend payouts. At current operating cash flows, the debt is serviceable but constrains financial flexibility for additional shareholder distributions.
What happens if hospital budgets contract or insurance coverage for ostomy products tightens?
Both risks would reduce unit volumes and push the company toward lower-margin channels or forced price concessions. The revenue mix already depends heavily on hospital and pharmacy purchasing decisions.
Is dividend income reliable from this company?
Dividends have been paid consistently, but they remain modest relative to earnings. Continued debt service takes priority; further increases are unlikely until leverage improves.
Where is most of the company's revenue coming from geographically?
The brief does not detail geographic revenue splits, only that distribution spans multiple countries and regions. Hospital and healthcare-provider concentration suggests developed-market weighting.
What is the CNVVY stock price today?
The last price recorded for ConvaTec Group Plc (CNVVY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 17 from Financial Modeling Prep (FMP) and 1 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com